Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients

Title:Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients

Volume: 9 Issue: 1

Author(s): Alessandra Romano, Giuseppina Uccello, Paolo Spina, Rosario Cunsolo, Calogero Vetro and Francesco Di Raimondo

Affiliation:

Keywords: Multiple myeloma, relapse, doxorubicin, salvage chemotherapy.

Abstract: Anthracyclines show anti myeloma effects, being part of active regimens like infusional vincristine/ doxorubicin/ pulsed dexamethasone (VAD) in the past and recently of bortezomib/doxorubicin/pulsed dexamethasone (PAD) for the treatment of multiple myeloma. The recent introduction of pegylated liposomal doxorubicin has led to the development of newer anthracycline-containing regimens with improved toxicity profiles.

In vitro, anthracyclines are able of suppressing bortezomib-mediated induction of some stress response proteins with a large synergic effect. Clinical trials have shown impressive activity of pegylated liposomal doxorubicin and conventional doxorubicin in combination with bortezomib in patients with relapsed/refractory myeloma. Herein, we review the clinical data supporting the use of pegylated liposomal doxorubicin combined to active agents in salvage regimens for relapsed/ refractory multiple myeloma patients.

Cite this article as:

Romano Alessandra, Uccello Giuseppina, Spina Paolo, Cunsolo Rosario, Vetro Calogero and Raimondo Di Francesco, Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients, Current Cancer Therapy Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573394711309010001